Prot #NU 16B14: I-CURE-1: A Phase II, single arm study of Pembrolizumab combined with carboplatin in patients with circulating tumor cells (CTCs) positive metastatic breast cancer (MBC)

Project: Research project

Project Details

StatusActive
Effective start/end date7/25/177/25/23

Funding

  • Merck Sharp & Dohme Corporation (Prot #NU 16B14)